Prostate Cancer | Specialty

Expert Projects Next Steps in Advanced Prostate Cancer

August 2nd 2016

Russell Szmulewitz, MD, discusses optimal treatment strategies for patients with metastatic castration-resistant prostate cancer and highlights emerging therapies in the therapeutic landscape.

Gyorgy Petrovics on Frequency of BRCA Mutations in African American Prostate Cancer Patients

August 2nd 2016

Gyorgy Petrovics, PhD, associate director, Center for Prostate Disease Research (CPDR), research associate professor in the department of surgery at the Uniformed Services University of the Health Sciences (USUHS), discusses BRCA1 and BRCA2 mutations in African American prostate cancer patients.

Expert Discusses Outcomes With Radiation Therapy in Locally Advanced Prostate Cancer

July 30th 2016

Stanley Liauw, MD, discusses the evolving role of radiation therapy in locally advanced prostate cancer and how it compares with surgical options.

Galeterone Prostate Cancer Trial Closes as PFS Rates Miss Mark

July 26th 2016

The pivotal phase III trial ARMOR 3-SV will be discontinued based on recommendations made by the trial's independent data monitoring committee.

Optimal Radium-223 Use Explored as Evolution of mCRPC Care Continues

July 26th 2016

Daniel P. Petrylak, MD, professor of Medicine, Yale Cancer Center, discusses his vision for radium-223 dichloride (Xofigo) in patients with metastatic castration-resistant prostate cancer and how it integrates with chemotherapy and other agents for treatment of this patient population.

Dreicer Addresses Key Questions With Radium-223 in mCRPC

July 25th 2016

Robert Dreicer, MD, discusses the key questions that surround the optimal use and sequencing of radium-223 dichloride (Xofigo) in patients with metastatic castration-resistant prostate cancer and how the treatment has altered the field of radiopharmaceuticals.

Dr. Oh on Recognizing Symptom Burden in Advanced Prostate Cancer

July 22nd 2016

William K. Oh, MD, professor of Medicine, Hematology, and Medical Oncology, and Urology, Mount Sinai Hospital, discusses a global study aimed at recognizing symptom burden in patients with advanced prostate cancer.

Expert Stresses Importance of PSA-Based Screening in Early-Stage Prostate Cancer

July 21st 2016

Scott Eggener, MD, discusses the implications of the Prostate, Lung, Colorectal, and Ovary trial update, and shares his views on PSA-based screening and how to appropriately use it for patients with early-stage prostate cancer.

CNS and Dose-Reduction Events After Abiraterone/Prednisone in mCRPC

July 19th 2016

Ajay S. Behl, PhD, Janssen Pharmaceuticals, discusses a study examining the central nervous system (CNS) and dose-reduction events in patients with prostate cancer following treatment with abiraterone acetate (Zytiga) plus prednisone.

Patnaik Highlights Evolution Toward Immunotherapy in Prostate Cancer

July 18th 2016

Akash Patnaik, MD, discusses immunotherapy and personalized medicine tactics in the field of prostate cancer, as well as the work that needs to be done with existing targeted therapies and biomarker development.

Dr. Charles Ryan on Impact of IMAAGEN Trial in Nonmetastatic CRPC

July 15th 2016

Dr. Crawford on Ongoing Research With Radium-223 in mCRPC

July 15th 2016

E. David Crawford, MD, professor of Radiation Oncology, Department of Surgery, University of Colorado Denver, discusses ongoing research with radium-223 dichloride (Xofigo) in patients with metastatic castration-resistant prostate cancer (mCRPC).

Stadler Shares Treatment Updates, Questions in Castration-Sensitive Prostate Cancer

July 12th 2016

Walter M. Stadler, MD, discusses emerging therapies, the most overriding challenges in a specific subset of patients, and understanding the evolving role of chemotherapy in metastatic castration-sensitive prostate cancer.

Dr. Taplin on ARMOR 3-SV Trial for Patients with mCRPC

July 11th 2016

Mary Ellen Taplin, MD, chair, executive committee for Clinical Research, director of Clinical Research, Lank Center for Genitourinary Oncology, institute physician, Dana-Farber Cancer Institute, associate professor of Medicine, Harvard Medical School, discusses the ongoing ARMOR 3-SV trial for patients with metastatic castration-resistant prostate cancer (mCRPC).

Dr. Loppenberg on Benefits of Local Treatment for Metastatic Prostate Cancer

July 11th 2016

Dr. Saad on Patients With mCRPC Eligible for 6-Doses of Radium-223

July 8th 2016

Fred Saad, MD, professor and chairman of Urology, director of GU Oncology, the University of Montreal Hospital Centers, discusses results of an analysis that examined which patients with metastatic castration-resistant prostate cancer are able to receive the recommended 6-doses of radium-223 dichloride (Xofigo).

Shore Shares Insight on Challenges of Bone Metastases in mCRPC

July 6th 2016

Bone metastases in castration-resistant prostate cancer create a significant problem, and a rising incidence of men are developing advanced disease.

GU Cancer Treatments Advance, But Their Application Remains Unclear

July 5th 2016

Even as our understanding of the biology of prostate and bladder cancers improves and treatment protocols are refined, there remain many clinical scenarios in which no clear-cut answers are available.

Dr. Marc Bjurlin on Predictive Models for Prostate Cancer Risk

June 29th 2016

Dr. Stacy Loeb on Screening Considerations in Prostate Cancer

June 28th 2016